Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dtap + sabin-strain inactivated poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- China National Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-sIPV is a combination vaccine developed primarily by Takeda Pharmaceuticals to provide protection against diphtheria, tetanus, pertussis, and poliomyelitis. It is distinguished by its use of inactivated poliovirus derived from attenuated Sabin strains (sIPV) rather than the traditional wild-type Salk strains. This substitution allows for manufacturing in lower-biosafety-level (BSL-2) facilities, which reduces production costs and biosafety risks compared to the BSL-3 requirements for wild-type poliovirus vaccines. The vaccine contains diphtheria and tetanus toxoids, acellular pertussis antigens (including pertussis toxoid, filamentous hemagglutinin, and pertactin), and inactivated poliovirus types 1, 2, and 3. It has been approved and marketed in Japan under the brand name Quattrovac and has undergone clinical investigation in other regions, including China.
- Brand names
- Quattrovac
- Other names
- DTaP-sIPVDTP-sIPVSabin-IPV-containing DTaPdiphtheria, tetanus, pertussis (acellular, component), and poliomyelitis (inactivated, sabin) vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)IPV1 (Inactivated poliovirus type 1)IPV2 (Inactivated poliovirus type 2)PV3 (Sabin) (Poliovirus type 3 antigen)
Beyond the preview
Go deeper on dtap + sabin-strain inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dtap + sabin-strain inactivated poliovirus vaccine.